Abstract: Provided is a bone regenerative agent which can repair a bone defect site with preventing from remaining at the bone defect site. The bone regenerative agent comprises zinc subcarbonate containing hydrozincite. It is preferred that the zinc subcarbonate has a Zn2+ ion elution amount of 0.1 ppm by mass or more after an elution test and also has a pH value of 7.2 or more and less than 8.3 after an elution test. It is preferred that some carbonate ions in the hydrozincite are substituted by sulfate ions or chloride ions. It is preferred that the bone regenerative agent is applied to a bone defect site.

Abstract: Focusing on zinc oxide itself, which is a main raw material for a zinc oxide varistor (laminated varistor), a predetermined amount of additive is added to a zinc oxide powder having crystallite size of 20 to 100 nm, particle diameter of 20 to 110 nm found using a specific area BET method, untamped density of 0.60 g/cm3 or greater, and tap density of 0.80 g/cm3 or greater. This allows a zinc oxide sintered body to secure uniformity, high density, and high electric conductivity, resulting in a zinc oxide varistor with high surge resistance, capable of downsizing and cost reduction. Moreover, addition of aluminum (Al), as a donor element, to the zinc oxide powder allows control of sintered grain size in conformity with the aluminum added amount and baking temperature, and also allows adjustment of varistor voltage, etc.

Abstract: Focus is on zinc oxide itself, which is a base material for a zinc oxide varistor (laminated varistor), wherein specified quantities of additives are added to a zinc oxide powder having a crystallite size of 20 to 50 nm, grain diameter of 15 to 60 nm found using the specific surface area BET method, untamped density of 0.38 to 0.50 g/cm3, and tap density of 0.50 to 1.00 g/cm3. This allows securing of uniformity, high compactness, and high electrical conductivity of a zinc oxide sintered body, and provision of a zinc oxide varistor having high surge resistance.

Abstract: The zinc oxide powder has a crystallite size of 20 to 50 nm as determined by X-ray diffraction, a particle diameter of 15 to 60 nm as determined by the BET method, a loose bulk density of 0.38 to 0.50 g/cm3, and a tapped density of 0.50 to 1.00 g/cm3. The zinc oxide powder has a small number of bound particles and a high tap density, and is useful as a raw material for obtaining a zinc oxide sintered body exhibiting high strength and low thermal conduction.

Abstract: A zinc oxide powder for producing a zinc oxide sintered body is provided with which it is possible to obtain a zinc oxide sintered body that has a small sintered particle size and high strength. This zinc oxide powder for producing a zinc oxide sintered body is used for producing a zinc oxide sintered body, wherein the Al content represented in formula (I) is greater than or equal to 20 mol ppm and less than or equal to 2 mol %. (I){nAl/(nZn+nAl)}×100. In formula (I), nAl represents the Al content in the zinc oxide powder, nZn represents the Zn content in the zinc oxide powder, and the unit of nZn and nAl is moles in both cases.

Abstract: A zinc oxide powder for producing a zinc oxide sintered body is provided with which it is possible to obtain a zinc oxide sintered body that has a large sintered particle size and excellent conductivity. This zinc oxide powder for producing a zinc oxide sintered body is used for producing a zinc oxide sintered body, wherein the Ga content represented in formula (I) is greater than or equal to 30 mol ppm and less than 3 mol %. (I) {nGa/(nZn+nGa)}×100 In formula (I), nGa represents the Ga content in the zinc oxide powder, nZn represents the Zn content in the zinc oxide powder, and the unit of nZn and nGa is moles in both cases.

Abstract: Focusing on zinc oxide itself, which is a main raw material for a zinc oxide varistor (laminated varistor), a predetermined amount of additive is added to a zinc oxide powder having crystallite size of 20 to 100 nm, particle diameter of 20 to 110 nm found using a specific area BET method, untamped density of 0.60 g/cm3 or greater, and tap density of 0.80 g/cm3 or greater. This allows a zinc oxide sintered body to secure uniformity, high density, and high electric conductivity, resulting in a zinc oxide varistor with high surge resistance, capable of downsizing and cost reduction. Moreover, addition of aluminum (Al), as a donor element, to the zinc oxide powder allows control of sintered grain size in conformity with the aluminum added amount and baking temperature, and also allows adjustment of varistor voltage, etc.

Abstract: Provided is a low-cost, easy-to-handle, effective therapeutic agent for wounds that is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide and may include a pharmaceutically acceptable carrier.

Abstract: An inorganic composition that is useful as an active ingredient for pharmaceuticals and has excellent stability comprises hydrozincite-containing zinc carbonate hydroxide hydrate produced by drying a precipitate. The precipitate is obtained by adding aqueous zinc nitrate solution, aqueous zinc sulfate solution or aqueous zinc chloride solution and aqueous sodium hydroxide solution dropwise to aqueous sodium hydrogen carbonate solution, a pH of the aqueous sodium hydrogen carbonate solution being maintained within a range of 6.5 to 9 by means of a pH controller. The hydrozincite-containing zinc carbonate hydroxide hydrate has an amount of dissolved Zn2+ ions of not less than 0.1 ?g/m2 but not more than 7.33 ?g/m2 and pH of not less than 7.2 and less than 8.3 after a dissolution test using stirring method.

Abstract: Provided is a low-cost, easy-to-handle, effective therapeutic agent for wounds that is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide and may include a pharmaceutically acceptable carrier.

Abstract: Provided is a low-cost, easy-to-handle, effective therapeutic agent for wounds that is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide and may include a pharmaceutically acceptable carrier.

Abstract: Disclosed is an inorganic composition which is useful as a base for pharmaceuticals and has excellent stability, and a method for producing the inorganic composition. The inorganic composition contains at least one compound selected from the group consisting of zinc sulfate, zinc chloride, zinc carbonate, zinc hydroxide, and zinc oxide, and has a pH of 7.2 or higher but lower than 8.3. After a dissolution test of the inorganic composition performed by a stirring method, the amount of Zn2* ions released therefrom is 0.1 pg/m2 or larger. This inorganic composition has the excellent property of gradually releasing zinc ions which makes the inorganic composition usable as a base for pharmaceuticals.

Abstract: Provided are: zinc chloride hydroxide that is useful as a pharmaceutical ingredient, has excellent zinc ion sustained-releasbility when used as a pharmaceutical agent, and exhibits excellent stability as a pharmaceutical ingredient; and a production method therefor. Disclosed is zinc chloride hydroxide that can be used as a pharmaceutical ingredient, that has excellent zinc ion sustained-releasability, that includes at least one member selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide.

Abstract: Focus is on zinc oxide itself, which is a base material for a zinc oxide varistor (laminated varistor), wherein specified quantities of additives are added to a zinc oxide powder having a crystallite size of 20 to 50 nm, grain diameter of 15 to 60 nm found using the specific surface area BET method, untamped density of 0.38 to 0.50 g/cm3, and tap density of 0.50 to 1.00 g/cm3. This allows securing of uniformity, high compactness, and high electrical conductivity of a zinc oxide sintered body, and provision of a zinc oxide varistor having high surge resistance.

Abstract: Provided is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc sulfate, zinc chloride, zinc carbonate, zinc hydroxide, and zinc oxide, may include a pharmaceutically acceptable carrier, and is effective in regenerating tissue.

Abstract: Provided is a low-cost, easy-to-handle, effective therapeutic agent for wounds that is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc chloride, zinc hydroxide, and zinc oxide and may include a pharmaceutically acceptable carrier.